Oncolytics Biotech Inc. (ONC.TO)
CAD 1.1
(-2.65%)
CAD 1.1
(-2.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -27.75 Million CAD | -11.75% |
| 2022 | -24.83 Million CAD | 5.59% |
| 2021 | -26.3 Million CAD | -34.54% |
| 2020 | -19.55 Million CAD | 57.08% |
| 2019 | -45.55 Million CAD | -167.37% |
| 2018 | -17.03 Million CAD | -9.1% |
| 2017 | -15.61 Million CAD | -3.15% |
| 2016 | -15.13 Million CAD | -10.33% |
| 2015 | -13.72 Million CAD | 26.3% |
| 2014 | -18.61 Million CAD | 20.88% |
| 2013 | -23.53 Million CAD | 35.3% |
| 2012 | -36.37 Million CAD | -25.23% |
| 2011 | -29.04 Million CAD | -45.41% |
| 2010 | -19.97 Million CAD | -17.52% |
| 2009 | -16.99 Million CAD | 3.16% |
| 2008 | -17.55 Million CAD | -12.2% |
| 2007 | -15.64 Million CAD | -9.4% |
| 2006 | -14.29 Million CAD | -11.86% |
| 2005 | -12.78 Million CAD | 1.35% |
| 2004 | -12.95 Million CAD | -51.64% |
| 2003 | -8.54 Million CAD | -40.26% |
| 2002 | -6.09 Million CAD | 1.3% |
| 2001 | -6.17 Million CAD | -70.81% |
| 2000 | -3.61 Million CAD | -528.96% |
| 1999 | -574.46 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -7.25 Million CAD | -5.25% |
| 2024 Q1 | -6.89 Million CAD | -74.58% |
| 2023 FY | -27.75 Million CAD | -11.75% |
| 2023 Q1 | -6.1 Million CAD | 28.6% |
| 2023 Q2 | -7.44 Million CAD | -21.82% |
| 2023 Q4 | -3.94 Million CAD | 60.21% |
| 2023 Q3 | -9.92 Million CAD | -33.38% |
| 2022 Q4 | -8.55 Million CAD | -94.1% |
| 2022 Q3 | -4.4 Million CAD | 13.5% |
| 2022 FY | -24.83 Million CAD | 5.59% |
| 2022 Q1 | -7.24 Million CAD | 6.51% |
| 2022 Q2 | -5.09 Million CAD | 29.7% |
| 2021 Q1 | -6.43 Million CAD | 31.02% |
| 2021 FY | -26.3 Million CAD | -34.54% |
| 2021 Q4 | -7.75 Million CAD | -59.09% |
| 2021 Q3 | -4.87 Million CAD | 32.76% |
| 2021 Q2 | -7.24 Million CAD | -12.61% |
| 2020 FY | -19.55 Million CAD | 57.08% |
| 2020 Q4 | -9.32 Million CAD | -38.23% |
| 2020 Q3 | -6.74 Million CAD | 1.15% |
| 2020 Q2 | -6.82 Million CAD | -1808.3% |
| 2020 Q1 | 399.66 Thousand CAD | 102.06% |
| 2019 Q1 | -4.93 Million CAD | -2.48% |
| 2019 FY | -45.55 Million CAD | -167.37% |
| 2019 Q4 | -19.4 Million CAD | -449.83% |
| 2019 Q3 | -3.52 Million CAD | 32.84% |
| 2019 Q2 | -5.25 Million CAD | -6.38% |
| 2018 Q2 | -4.21 Million CAD | 9.83% |
| 2018 Q3 | -3.33 Million CAD | 20.79% |
| 2018 FY | -17.03 Million CAD | -9.1% |
| 2018 Q4 | -4.81 Million CAD | -44.47% |
| 2018 Q1 | -4.67 Million CAD | 1.58% |
| 2017 FY | -15.61 Million CAD | -3.15% |
| 2017 Q4 | -4.74 Million CAD | -57.95% |
| 2017 Q3 | -3 Million CAD | 30.92% |
| 2017 Q2 | -4.34 Million CAD | -23.64% |
| 2017 Q1 | -3.51 Million CAD | 32.48% |
| 2016 Q3 | -3.33 Million CAD | -29.13% |
| 2016 Q1 | -4.01 Million CAD | -14.87% |
| 2016 FY | -15.13 Million CAD | -10.33% |
| 2016 Q4 | -5.21 Million CAD | -56.34% |
| 2016 Q2 | -2.58 Million CAD | 35.75% |
| 2015 Q4 | -3.49 Million CAD | -23.83% |
| 2015 Q2 | -3.85 Million CAD | -8.4% |
| 2015 Q1 | -3.55 Million CAD | 6.01% |
| 2015 FY | -13.72 Million CAD | 26.3% |
| 2015 Q3 | -2.82 Million CAD | 26.65% |
| 2014 Q3 | -4.63 Million CAD | 1.73% |
| 2014 Q1 | -5.48 Million CAD | 5.3% |
| 2014 Q4 | -3.77 Million CAD | 18.49% |
| 2014 Q2 | -4.71 Million CAD | 13.99% |
| 2014 FY | -18.61 Million CAD | 20.88% |
| 2013 Q2 | -5.01 Million CAD | 24.02% |
| 2013 FY | -23.53 Million CAD | 35.3% |
| 2013 Q4 | -5.79 Million CAD | 5.25% |
| 2013 Q3 | -6.11 Million CAD | -21.79% |
| 2013 Q1 | -6.6 Million CAD | 22.2% |
| 2012 Q1 | -8.45 Million CAD | 27.56% |
| 2012 Q2 | -10.17 Million CAD | -20.34% |
| 2012 FY | -36.37 Million CAD | -25.23% |
| 2012 Q3 | -9.24 Million CAD | 9.18% |
| 2012 Q4 | -8.49 Million CAD | 8.13% |
| 2011 Q3 | -6.23 Million CAD | 13.01% |
| 2011 FY | -29.04 Million CAD | -45.41% |
| 2011 Q1 | -3.97 Million CAD | 46.85% |
| 2011 Q2 | -7.16 Million CAD | -80.41% |
| 2011 Q4 | -11.67 Million CAD | -87.38% |
| 2010 Q4 | -7.47 Million CAD | -86.37% |
| 2010 Q3 | -4 Million CAD | 7.88% |
| 2010 Q2 | -4.35 Million CAD | -5.09% |
| 2010 FY | -19.97 Million CAD | -17.52% |
| 2010 Q1 | -4.14 Million CAD | 21.04% |
| 2009 Q3 | -2.69 Million CAD | 37.85% |
| 2009 FY | -16.99 Million CAD | 3.16% |
| 2009 Q1 | -3.95 Million CAD | 16.86% |
| 2009 Q2 | -4.33 Million CAD | -9.53% |
| 2009 Q4 | -5.24 Million CAD | -94.69% |
| 2008 Q4 | -4.76 Million CAD | -14.96% |
| 2008 FY | -17.55 Million CAD | -12.2% |
| 2008 Q1 | -3.32 Million CAD | 18.63% |
| 2008 Q2 | -5.25 Million CAD | -58.07% |
| 2008 Q3 | -4.14 Million CAD | 21.2% |
| 2007 Q2 | -3.67 Million CAD | 10.54% |
| 2007 FY | -15.64 Million CAD | -9.4% |
| 2007 Q4 | -4.08 Million CAD | -8.54% |
| 2007 Q3 | -3.76 Million CAD | -2.29% |
| 2007 Q1 | -4.11 Million CAD | 15.89% |
| 2006 FY | -14.29 Million CAD | -11.86% |
| 2006 Q3 | -3.42 Million CAD | -14.64% |
| 2006 Q2 | -2.98 Million CAD | 0.23% |
| 2006 Q4 | -4.89 Million CAD | -42.77% |
| 2006 Q1 | -2.99 Million CAD | -19.15% |
| 2005 Q1 | -2.37 Million CAD | 40.45% |
| 2005 Q2 | -2.95 Million CAD | -24.3% |
| 2005 FY | -12.78 Million CAD | 1.35% |
| 2005 Q3 | -4.07 Million CAD | -37.95% |
| 2005 Q4 | -2.51 Million CAD | 38.34% |
| 2004 Q1 | -2.67 Million CAD | -57.84% |
| 2004 Q4 | -3.99 Million CAD | -28.94% |
| 2004 Q2 | -3.19 Million CAD | -19.27% |
| 2004 Q3 | -3.09 Million CAD | 3.0% |
| 2004 FY | -12.95 Million CAD | -51.64% |
| 2003 Q1 | -1.11 Million CAD | 27.74% |
| 2003 FY | -8.54 Million CAD | -40.26% |
| 2003 Q4 | -1.69 Million CAD | 6.97% |
| 2003 Q3 | -1.82 Million CAD | 53.92% |
| 2003 Q2 | -3.95 Million CAD | -254.95% |
| 2002 Q1 | -1.27 Million CAD | 6.04% |
| 2002 FY | -6.09 Million CAD | 1.3% |
| 2002 Q4 | -1.54 Million CAD | 22.5% |
| 2002 Q3 | -1.98 Million CAD | -54.78% |
| 2002 Q2 | -1.28 Million CAD | -0.92% |
| 2001 FY | -6.17 Million CAD | -70.81% |
| 2001 Q2 | -1.35 Million CAD | -33.68% |
| 2001 Q3 | -2.44 Million CAD | -80.38% |
| 2001 Q1 | -1.01 Million CAD | -98.37% |
| 2001 Q4 | -1.35 Million CAD | 44.57% |
| 2000 Q1 | -269.91 Thousand CAD | 0.0% |
| 2000 Q2 | -1.27 Million CAD | -371.91% |
| 2000 Q3 | -1.55 Million CAD | -22.33% |
| 2000 Q4 | -511.29 Thousand CAD | 67.19% |
| 2000 FY | -3.61 Million CAD | -528.96% |
| 1999 FY | -574.46 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -3.78 Million CAD | -634.003% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 25.78% |
| Helix BioPharma Corp. | -9.26 Million CAD | -199.568% |
| Microbix Biosystems Inc. | -39.48 Thousand CAD | -70188.479% |
| Medicenna Therapeutics Corp. | -25.46 Million CAD | -8.977% |
| Satellos Bioscience Inc. | -15.88 Million CAD | -74.662% |
| Sernova Corp. | -38.99 Million CAD | 28.837% |